News | May 16, 2025
Piramal Pharma reports Q4 FY25 consolidated net profit of Rs. 153.50 Cr
The company has posted net profit of Rs. 91.13 crores for the Financial Year ended March 31, 2025
The company has posted net profit of Rs. 91.13 crores for the Financial Year ended March 31, 2025
For the full financial year FY25, revenue from operations grew 9 per cent to Rs. 11,537.8 crore, compared to Rs. 10,588 crore in FY24.
EBITDA before special items decreases to €4.08 billion (7.4%)
_256_384.jpg)
The company reported 30.1% jump in Q4 FY25 PAT at Rs. 1,222 crore
The Board of Directors of the company recommends a final dividend of Rs. 42 per equity share for the 12 months period ended March 31, 2025
The Q1 2025 also witnessed a successful launch of Allegra D
The positive opinions are based on applications submitted by Biosimilar Collaborations Ireland Limited
Distribution agreement enables FUJIFILM India to offer Spectra Logic advanced tape libraries and software solutions to enterprise customers and channel partners
The merged entity ‘Aster DM Quality Care’ will be jointly controlled by Aster Promoters and Blackstone
Expanded US manufacturing and R&D presence with investment in 10 facilities, including 7 brand new facilities
Subscribe To Our Newsletter & Stay Updated
